These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 31982288)
1. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial. Murata M; Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K Parkinsonism Relat Disord; 2020 Jul; 76():91-97. PubMed ID: 31982288 [TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial. Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K; Murata M Am J Geriatr Psychiatry; 2022 Mar; 30(3):314-328. PubMed ID: 34420834 [TBL] [Abstract][Full Text] [Related]
3. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study. Murata M; Odawara T; Hasegawa K; Iiyama S; Nakamura M; Tagawa M; Kosaka K Neurology; 2018 Feb; 90(8):e664-e672. PubMed ID: 29367449 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials. Hasegawa K; Kochi K; Maruyama H; Konishi O; Toya S; Odawara T J Alzheimers Dis; 2021; 79(2):627-637. PubMed ID: 33337365 [TBL] [Abstract][Full Text] [Related]
5. The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data. Tousi B; Leverenz JB Drug Des Devel Ther; 2021; 15():1811-1817. PubMed ID: 33976533 [TBL] [Abstract][Full Text] [Related]
6. Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review. Kong L; Xi J; Jiang Z; Yu X; Liu H; Wang Z Biomed Res Int; 2022; 2022():4817488. PubMed ID: 36132085 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study. Ikeda M; Mori E; Orimo S; Yamada T; Konishi O J Alzheimers Dis; 2023; 95(1):251-264. PubMed ID: 37483001 [TBL] [Abstract][Full Text] [Related]
8. Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials. Tsuboi Y; Kochi K; Maruyama H; Matsumoto Y eNeurologicalSci; 2022 Mar; 26():100384. PubMed ID: 34988303 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism. Panza F; Lozupone M; Watling M; Imbimbo BP Expert Opin Pharmacother; 2021 Feb; 22(3):325-337. PubMed ID: 33021110 [TBL] [Abstract][Full Text] [Related]
10. Invited Perspective on the "Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial". Hinkle JT; Pontone GM Am J Geriatr Psychiatry; 2022 Mar; 30(3):329-331. PubMed ID: 34429237 [No Abstract] [Full Text] [Related]
11. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R; Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148 [TBL] [Abstract][Full Text] [Related]
12. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613 [TBL] [Abstract][Full Text] [Related]
13. Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials. Tsuboi Y; Nakamura M; Maruyama H; Matsumoto Y J Neurol Sci; 2021 Nov; 430():120026. PubMed ID: 34715471 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological Management of Dementia with Lewy Bodies. Hershey LA; Coleman-Jackson R Drugs Aging; 2019 Apr; 36(4):309-319. PubMed ID: 30680679 [TBL] [Abstract][Full Text] [Related]
15. An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). Lang FM; Kwon DY; Aarsland D; Boeve B; Tousi B; Harnett M; Mo Y; Noel Sabbagh M Alzheimers Dement (N Y); 2021; 7(1):e12171. PubMed ID: 34189249 [TBL] [Abstract][Full Text] [Related]
16. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D; Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699 [TBL] [Abstract][Full Text] [Related]
17. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Thomas AJ; Burn DJ; Rowan EN; Littlewood E; Newby J; Cousins D; Pakrasi S; Richardson J; Sanders J; McKeith IG Int J Geriatr Psychiatry; 2005 Oct; 20(10):938-44. PubMed ID: 16163744 [TBL] [Abstract][Full Text] [Related]
18. Effects of Donepezil on Extrapyramidal Symptoms in Patients with Dementia with Lewy Bodies: A Secondary Pooled Analysis of Two Randomized-Controlled and Two Open-Label Long-Term Extension Studies. Mori E; Ikeda M; Nakagawa M; Miyagishi H; Yamaguchi H; Kosaka K Dement Geriatr Cogn Disord; 2015; 40(3-4):186-98. PubMed ID: 26226884 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C; Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]